Cannabis allergy: what the clinician needs to know in 2019.
Can s 3
Cannabis
allergy
basophil activation
hemp
non-specific lipid transfer protein (nsLTP)
skin prick test
specific IgE
Journal
Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
5
4
2019
medline:
12
6
2020
entrez:
5
4
2019
Statut:
ppublish
Résumé
Although the use of cannabis dates back millennia, the first description of cannabis allergy is relatively recent (1971). Recent large-scale data show that cannabis allergy can manifest severe and generalized symptoms with extensive cross-reactions. Thus, it is essential to become familiarized with its clinical presentation, diagnostic aids, and adequate therapeutic guidance. Areas covered: Here we provide a hands-on overview on cannabis allergy focusing on symptomatology and the reliability of diagnostic options. Recent advances in proteomics are discussed in detail, elucidating the link with nsLTP-related allergies. The proteomics advancements have paved the way for more reliable diagnostics, especially component-based tools. Finally, the current experience in treatment options is highlighted. Expert opinion: Cannabis allergy is an allergy entity which can significantly impact the quality of life. For optimal diagnosis, we advise to start with a validated and standardized crude-extract based test such as sIgE hemp complemented by component-based diagnostics such as sIgE Can s 3 quantifications where available. Future research should lift the veil on the true prevalence of cannabis allergy and the importance of other cannabis allergens to further guide our practice.
Identifiants
pubmed: 30946607
doi: 10.1080/1744666X.2019.1600403
doi:
Substances chimiques
Antigens, Plant
0
Can s 3 allergen, Cannabis sativa
0
Carrier Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM